Evaluation of preclinical antimalarial drugs, which can overcome direct-acting antivirals-resistant hepatitis C viruses, using the viral reporter assay systems-Reference-Cited by-同舟云学术

Evaluation of preclinical antimalarial drugs, which can overcome direct-acting antivirals-resistant hepatitis C viruses, using the viral reporter assay systems

Published:2017-05 Issue: Volume:235 Page:37-48
ISSN:0168-1702
Container-title:Virus Research
language:en
Short-container-title:Virus Research

Author:

Ueda Youki,Dansako Hiromichi,Satoh Shinya,Kim Hye-Sook,Wataya Yusuke,Doi Hiroyuki,Ikeda Masanori,Kato Nobuyuki

Funder

Japan Agency for Medical Research and Development

JSPS KAKENHI

Publisher

Elsevier BV

Subject

Cancer Research,Infectious Diseases,Virology

Reference50 articles.

1. Cell culture-adaptive NS3 mutations required for the robust replication of genome-length hepatitis C virus RNA;Abe;Virus Res.,2007

2. Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response;Bichoupan;Hepatology,2014

3. Efficient initiation of HCV RNA replication in cell culture;Blight;Science,2000

4. Advances in experimental systems to study hepatitis C virus in vitro and in vivo;Catanese;Virology,2015

5. Interferon-based therapy of hepatitis C;Chevaliez;Adv. Drug Deliv. Rev.,2007

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiviral mechanism of preclinical antimalarial compounds possessing multiple antiviral activities;FASEB BioAdvances;2021-03-04

2. Hepatitis C virus (HCV) : Development of anti-HCV agents and anti-HCV therapy;Okayama Igakkai Zasshi (Journal of Okayama Medical Association);2020-12-01

3. Comparative study on the replication of HCV1b genome between wild‐type and cell culture‐adaptive mutant in regard to sensitivities against anti‐HCV drugs;Microbiology and Immunology;2020-01-31

4. Study of multiple genetic variations caused by persistent hepatitis C virus replication in long-term cell culture;Archives of Virology;2019-12-12

5. A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens;Biomedicine & Pharmacotherapy;2019-08